Longevity Health Holdings, Inc.
For the period ended Mar 31, 2026. Filed May 15, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 15, 2026
XAGE$0.130.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
| Three Months Ended March 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Cash flows from operating activities: | ||
| Net loss from continuing operations | $(1,431,713) | $(1,505,867) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation | 145,927 | 114,829 |
| Depreciation and amortization of intangible assets | 15,038 | 23,952 |
| Amortization of right of use assets | 22,282 | 49,756 |
| Change in fair value of earnout liabilities | (96,053) | — |
| Inventory write-down | 196,684 | — |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | (12,165) | (14,102) |
| Inventory | 31,376 | 15,204 |
| Prepaid expenses | 101,532 | 145,130 |
| Accounts payable | 551,354 | 317,040 |
| Accrued expenses and other liabilities | 15,112 | 149,392 |
| Lease liability | (24,665) | (48,287) |
| Net cash used in operating activities | (485,291) | (752,953) |
| Cash flows from investing activities | ||
| Cash paid for Elevai Acquisition transaction costs | — | (150,000) |
| Net cash used in investing activities | — | (150,000) |
| Cash flows from financing activities: | ||
| Proceeds from issuance of Common Stock, net of costs | 190,001 | 1,637,610 |
| Repayment of loans | (98,054) | (121,749) |
| Net cash provided by financing activities | 91,947 | 1,515,861 |
| Net (decrease) increase in cash and cash equivalents | (393,344) | 612,908 |
| Cash and cash equivalents - beginning of period | 706,740 | 157,139 |
| Cash and cash equivalents - end of period | $313,396 | $770,047 |
-6-
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Continued)
| Three Months Ended March 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Supplemental cash flow information: | ||
| Interest paid | $3,450 | $4,993 |
| Income taxes paid | — | — |
| Non-cash investing and financing activities: | ||
| Insurance premium financing agreements | $23,457 | $— |
| Fair value of shares issued in Elevai Acquisition | 67,742 | 660,805 |
| Consideration payable | — | 67,742 |
| Earnout liabilities in Elevai Acquisition | — | 301,633 |
-7-
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.